COST-UTILITY ANALYSIS OF SECUKINUMAB USE VERSUS TNF-? INHIBITORS, IN PATIENTS WITH ANKYLOSING SPONDILYTIS

OBJECTIVES: To assess the cost-utility of secukinumab in the treatment of ankylosing spondylitis (AS) patients in Colombia versus TNF-a inhibitors METHODS: The cost-effectiveness model captures health benefits (measured by quality-adjusted life years [QALYs]) and costs associated with the use of sec...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2017-10, Vol.20 (9), p.A938
Hauptverfasser:	Prada, ME Romero, Cardenas, NC Roa, Serrano, GY, Huerfano, LM
Format:	Artikel
Sprache:	eng
Schlagworte:	Ankylosing spondylitis Baths Cost analysis Critical incidents Discontinued Etanercept Health care expenditures Infliximab Inhibitor drugs Medical treatment Meta-analysis Monoclonal antibodies Patients Quality of life Rheumatic diseases Spondylitis Tariffs Tumor necrosis factor-TNF Tumor necrosis factor-α Utility functions
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!